REGORAFENIB IN GLIOBLASTOMA: in vitro CHARACTERIZATION OF TUMOR CELLS RESPONSE

Glioblastoma IDH wild-type (GBM), is the most malignant primary brain tumor in adults. A phase II clinical trial (REGOMA)1 demonstrated that the multikinase inhibitor regorafenib significantly increased the median overall survival of GBM patients when compared to lomustine-treated patients. On this basis, the National Comprehensive Cancer Network (NCCN) 2020 Guidelines included Regorafenib as a preferred regimen in relapsed GBM treatment. However, very little is known about the mechanisms governing GBM cells response to regorafenib. Here we report an in vitro characterization of GBM tumor cells’ response to regorafenib, performed both on cell lines and on patient-derived glioma stem cells (GSCs)